Colombia Pharmaceuticals & Healthcare Report Q2 2014 - New Market Research Report
As BMI's July 2013 forecast for government drug pricing pressure to increase in Colombia has materialised, we now believe drugmakers' revenue streams will continue to be constrained over the coming years. On the positive side, we expect volume sales will be boosted and partially offset the negative impacts of further drug price cuts. Colombia's relatively advanced drug reimbursement system will still offer revenue-generating opportunities for multinationals in comparison with other second-tier Latin American pharmaceutical markets.
View full press release